Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or intravenous administration, offering a ready-to-use option for patients ...

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces ...

BRIDGEWATER, N.J., April 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today ...

Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price ...

Amneal Pharmaceuticals (AMRX) announced Thursday that insurance coverage accounts, the Veterans Administration, UnitedHealthcare (NYSE:UNH) and CVS Health (NYSE:CVS), have added its Crexont ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of ...

Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the prior year, the firm earned $0.14 EPS.

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a strategy that has led to a 45% increase in its ...

Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma. Credit: SmartPhotoLab/Shutterstock. Amneal Pharmaceuticals and ...